Brief: Oramed Pharmaceuticals Inc - Currently Advancing Two Primary Programs: Oral Insulin For Diabetes And An Oral Covid Vaccine
25/05/2021 14:33
May 25 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED PHARMACEUTICALS INC - CURRENTLY ADVANCING TWO
PRIMARY
PROGRAMS: ORAL INSULIN FOR DIABETES AND AN ORAL COVID VACCINE
* ORAMED PHARMACEUTICALS INC - ANTICIPATE COMPLETING
ENROLLMENT
FOR U.S. STUDY, ORA-D-013-1, OF ORMD-0801 BEFORE 2021 END
Source text for Eikon: ID:nPn3q2bka
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results